Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Potential for huge innovations are overstated – the FDA isn’t even approving innovative drugs post the Aduhelm scandal.

GlobalData Healthcare January 30, 2023 Decline of novel drug approvals means less business for cutting-edge CMOs https://www.pharmaceutical-technology.com/comment/decline-of-novel-drug-approvals/

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. This is due to generally more stringent criteria on approvals in the wake of the Aduhelm scandal. However, non-NME and biosimilar approvals increased in 2022. This is mixed news for contract manufacturing organisations (CMOs), as large CMOs such as (Waltham, MA, US) and Inc (Somerset, NJ, US) are typically involved in the manufacture of the most innovative products. In 2023, there will be opportunities for a wider range of CMOs that can offer services for less innovative drugs requiring reformulation or biosimilar production. Increased reluctance to authorise innovative and unproven drugs for use, stemming from the FDA’s experience with Aduhelm, reduced the overall novel approvals in 2022. In June 2021, the FDA granted accelerated approval of ’s (Cambridge, MA, US) Aduhelm (aducanumab-avwa) for Alzheimer’s disease, despite there being questionable evidence of clinical benefit and the majority of an FDA advisory panel voting against the drug’s approval. The approval was based on claims that the drug led to a reduction in amyloid plaques in the brain. However, Alzheimer’s disease is a complex illness, and its cause and pathophysiology are poorly understood. Aduhelm is both costly and commonly produces side effects.

Sign in to recut, update, or save this card.